Published in Am J Gastroenterol on March 02, 2010
A genome-wide association study on chronic HBV infection and its clinical progression in male Han-Taiwanese. PLoS One (2014) 0.89
Inverse association between hepatitis B virus infection and fatty liver disease: a large-scale study in populations seeking for check-up. PLoS One (2013) 0.88
Cohort profile: golestan hepatitis B cohort study- a prospective long term study in northern iran . Middle East J Dig Dis (2014) 0.82
Artificial neural network accurately predicts hepatitis B surface antigen seroclearance. PLoS One (2014) 0.81
Dynamic Characteristics of Serum Hepatitis B Surface Antigen in Chinese Chronic Hepatitis B Patients Receiving 7 Years of Entecavir Therapy. Chin Med J (Engl) (2016) 0.79
Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses. PLoS One (2011) 0.79
HBsAg seroclearance and mortality. Am J Gastroenterol (2010) 0.75
Effects of sex and generation on hepatitis B viral load in families with hepatocellular carcinoma. World J Gastroenterol (2017) 0.75
Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med (2002) 6.20
Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med (2007) 6.11
Hepatitis B virus infection. Lancet (2009) 5.78
Risk factors of pneumothorax and bleeding: multivariate analysis of 660 CT-guided coaxial cutting needle lung biopsies. Chest (2004) 3.80
Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology (2010) 3.57
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol (2010) 3.55
Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst (2005) 3.48
Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst (2008) 3.27
Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology (2007) 3.08
Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology (2002) 2.83
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks. Hepatology (2008) 2.70
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol (2009) 2.39
HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology (2007) 2.36
Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology (2013) 2.29
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology (2002) 2.12
HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology (2008) 2.11
Cranberry-containing products for prevention of urinary tract infections in susceptible populations: a systematic review and meta-analysis of randomized controlled trials. Arch Intern Med (2012) 2.05
Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol (2006) 2.03
Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol (2007) 1.90
Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology (2004) 1.85
Carriers of inactive hepatitis B virus are still at risk for hepatocellular carcinoma and liver-related death. Gastroenterology (2010) 1.69
Identification of a hepatitis B virus S gene mutant in lamivudine-treated patients experiencing HBsAg seroclearance. Gastroenterology (2006) 1.62
A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology (2006) 1.62
Predictors of long-term disease-free survival after resection of hepatocellular carcinoma: two decades of experience at Chang Gung Memorial Hospital. Ann Surg Oncol (2003) 1.60
Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology (2002) 1.60
Decreasing levels of HBsAg predict HBsAg seroclearance in patients with inactive chronic hepatitis B virus infection. Clin Gastroenterol Hepatol (2011) 1.48
A sustained virological response to interferon or interferon/ribavirin reduces hepatocellular carcinoma and improves survival in chronic hepatitis C: a nationwide, multicentre study in Taiwan. Antivir Ther (2006) 1.48
Determinants for sustained HBeAg response to lamivudine therapy. Hepatology (2003) 1.38
Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int (2011) 1.30
Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med (2004) 1.29
The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B. J Hepatol (2003) 1.29
Role of reproductive factors in hepatocellular carcinoma: Impact on hepatitis B- and C-related risk. Hepatology (2003) 1.28
Penoscrotal extramammary Paget's disease: a review of 33 cases in a 20-year experience. Plast Reconstr Surg (2003) 1.28
Predictive factors for reactivation of hepatitis B following hepatitis B e antigen seroconversion in chronic hepatitis B. Gastroenterology (2007) 1.27
Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time. Hepatology (2009) 1.27
Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology (2013) 1.26
Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol (2012) 1.23
Hepatitis B virus-related cirrhosis: natural history and treatment. Semin Liver Dis (2006) 1.22
Glaucoma is associated with peripheral vascular endothelial dysfunction. Ophthalmology (2008) 1.22
A 162-case review of palatal fracture: management strategy from a 10-year experience. Plast Reconstr Surg (2008) 1.21
Frontal sinus fractures: a treatment algorithm and assessment of outcomes based on 78 clinical cases. Plast Reconstr Surg (2006) 1.19
Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: a systematic review. J Hepatol (2012) 1.17
Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer (2004) 1.16
Traumatic superior orbital fissure syndrome: assessment of cranial nerve recovery in 33 cases. Plast Reconstr Surg (2010) 1.16
Association of cytokine and DNA repair gene polymorphisms with hepatitis B-related hepatocellular carcinoma. Int J Epidemiol (2005) 1.16
Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther (2010) 1.10
Incidence and risk factors of progression to cirrhosis in inactive carriers of hepatitis B virus. Am J Gastroenterol (2009) 1.07
Association between endothelial dysfunction and hyperuricaemia. Rheumatology (Oxford) (2010) 1.03
Precore stop mutant in HBeAg-positive patients with chronic hepatitis B: clinical characteristics and correlation with the course of HBeAg-to-anti-HBe seroconversion. J Clin Microbiol (2002) 1.02
The efficacy and safety of topically applied indigo naturalis ointment in patients with plaque-type psoriasis. Dermatology (2007) 1.01
Factors affecting diagnostic accuracy of CT-guided coaxial cutting needle lung biopsy: retrospective analysis of 631 procedures. J Vasc Interv Radiol (2003) 1.01
Increased levels of F2-isoprostanes following aneurysmal subarachnoid hemorrhage in humans. Free Radic Biol Med (2006) 1.01
Spontaneous relapse of hepatitis in inactive HBsAg carriers. Hepatol Int (2007) 0.98
Polymorphisms in XRCC1 and glutathione S-transferase genes and hepatitis B-related hepatocellular carcinoma. J Natl Cancer Inst (2003) 0.97
Neighboring-cation substitution tuning of photoluminescence by remote-controlled activator in phosphor lattice. J Am Chem Soc (2013) 0.96
Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations. AJR Am J Roentgenol (2008) 0.96
Activation of Th1 immunity is a common immune mechanism for the successful treatment of hepatitis B and C: tetramer assay and therapeutic implications. J Biomed Sci (2003) 0.95
Multivariate analysis of clinical prognostic factors in children with intracranial ependymomas. J Neurooncol (2004) 0.94
Age-specific prognosis following spontaneous hepatitis B e antigen seroconversion in chronic hepatitis B. Hepatology (2010) 0.94
Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int (2007) 0.94
Hepatitis B virus transmission and hepatocarcinogenesis: a 9 year retrospective cohort of 13676 relatives with hepatocellular carcinoma. J Hepatol (2004) 0.93
Hepatitis B virus core variants modify natural course of viral infection and hepatocellular carcinoma progression. Gastroenterology (2009) 0.92
Hepatitis C virus infection facilitates gallstone formation. J Gastroenterol Hepatol (2005) 0.91
Significance of coronary calcification for prediction of coronary artery disease and cardiac events based on 64-slice coronary computed tomography angiography. Biomed Res Int (2013) 0.91
Altered expression patterns of lipid metabolism genes in an animal model of HCV core-related, nonobese, modest hepatic steatosis. BMC Genomics (2008) 0.91
Chronic hepatitis B: past, present, and future. Clin Liver Dis (2010) 0.90
Viral load, genotypes, and mutants in hepatitis B virus-related hepatocellular carcinoma: special emphasis on patients with early hepatocellular carcinoma. Dig Dis Sci (2011) 0.90
Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B. Clin Gastroenterol Hepatol (2010) 0.90
One-step synthesis of uniform silver nanoparticles capped by saturated decanoate: direct spray printing ink to form metallic silver films. Phys Chem Chem Phys (2009) 0.89
Increased risk for hepatitis B-related liver cirrhosis in relatives of patients with hepatocellular carcinoma in northern Taiwan. Int J Epidemiol (2002) 0.89
Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer (2012) 0.89
Virus and transaminase levels determine the emergence of drug resistance during long-term lamivudine therapy in chronic hepatitis B. J Hepatol (2005) 0.88
Bacteriology of acute appendicitis and its implication for the use of prophylactic antibiotics. Surg Infect (Larchmt) (2012) 0.87
Withdrawal of lamivudine in HBeAg-positive chronic hepatitis B patients after achieving effective maintained virological suppression. J Clin Virol (2009) 0.87
Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther (2009) 0.86
Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without. Dig Dis Sci (2012) 0.86
Origin of thermal degradation of Sr(2-x)Si5N8:Eu(x) phosphors in air for light-emitting diodes. J Am Chem Soc (2012) 0.86
Outcome for traumatic optic neuropathy--surgical versus nonsurgical treatment. Ann Plast Surg (2004) 0.86
Genetic alterations of INK4alpha/ARF locus and p53 in human hepatocellular carcinoma. Anticancer Res (2002) 0.86
Androgen receptor exon 1 CAG repeat length and risk of hepatocellular carcinoma in women. Hepatology (2002) 0.86
Combination antifungal therapy for disseminated fusariosis in immunocompromised patients : a case report and literature review. Med Mycol (2011) 0.86
Rescue therapy for lamivudine-resistant chronic hepatitis B: when and how? Hepatology (2007) 0.85
Clinical manifestations, course, and outcome of patients with neutralizing anti-interferon-γ autoantibodies and disseminated nontuberculous mycobacterial infections. Medicine (Baltimore) (2016) 0.85
Short-term lamivudine therapy in HBeAg-negative chronic active hepatitis B in Taiwan. Antivir Ther (2006) 0.84
Arylamine-based dyes for p-type dye-sensitized solar cells. Org Lett (2011) 0.84
A self-assembled microbonded germanium/silicon heterojunction photodiode for 25 Gb/s high-speed optical interconnects. Sci Rep (2013) 0.83
Hepatitis B viraemia: its heritability and association with common genetic variation in the interferon gamma signalling pathway. Gut (2010) 0.83